MI Cloud allows all employees, regardless of rank, democratic access to cutting edge market research data. It helps B2B companies translate growth intelligence to revenue intelligence, enables teams and partners to collaborate on analysis, insights and decision making while identifying niche market opportunities arising out of disruptions. It also enables gathering of intelligence by taking advantage of proven and highly scalable data analysis and insights.

YC shift: MNM research also showed that the major customer segments such as pharma and life sciences companies are facing a growing need for digital transformation to boost their R&D productivity. This will lead to increasing deployment of AI and cloud-based products, fuelling growth for the client’s translational R&D DSS. Customers' needs were also shifting towards solutions offering multiple modalities, but the market was fragmented with the presence of many small and mid-sized players focusing on single modality solutions. Thus, our analysis showed that our client could beat its competitors by offering holistic, multimodality solutions, which execute all functionalities.

Interconnections: Biomarker discovery for various disease indications, e.g. cardiovascular disorders, neurological disorders, etc is being executed using translational R&D DSS – making it attractive for the client apart from conventional oncology applications.

Unknown: Different functionalities of the product such as data aggregation can be managed using blockchain technology. Further, increased incorporation of big data technology in translational R&D DSS could also be a game-changer for product development, particularly in drug discovery and clinical research involving real-world patient data and other data sets.